BR0207434A - Uso de agentes de domiciliação acelerada de linfócitos para a fabricação de um medicamento para o tratamento de função retardada de enxertos - Google Patents

Uso de agentes de domiciliação acelerada de linfócitos para a fabricação de um medicamento para o tratamento de função retardada de enxertos

Info

Publication number
BR0207434A
BR0207434A BR0207434-6A BR0207434A BR0207434A BR 0207434 A BR0207434 A BR 0207434A BR 0207434 A BR0207434 A BR 0207434A BR 0207434 A BR0207434 A BR 0207434A
Authority
BR
Brazil
Prior art keywords
accelerated
domiciliation
lymphocyte
medicament
agents
Prior art date
Application number
BR0207434-6A
Other languages
English (en)
Portuguese (pt)
Inventor
Marc Bigaud
Volker Brinkmann
Tomasz Sablinski
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0104438A external-priority patent/GB0104438D0/en
Priority claimed from GB0105000A external-priority patent/GB0105000D0/en
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of BR0207434A publication Critical patent/BR0207434A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/133—Amines having hydroxy groups, e.g. sphingosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/131—Amines acyclic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/201—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having one or two double bonds, e.g. oleic, linoleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
BR0207434-6A 2001-02-22 2002-02-21 Uso de agentes de domiciliação acelerada de linfócitos para a fabricação de um medicamento para o tratamento de função retardada de enxertos BR0207434A (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0104438A GB0104438D0 (en) 2001-02-22 2001-02-22 Organic compounds
GB0105000A GB0105000D0 (en) 2001-02-28 2001-02-28 Organic compounds
PCT/EP2002/001860 WO2002067915A1 (en) 2001-02-22 2002-02-21 Use of accelerated lymphocyte homing agents for the manufacture of a medicament for the treatment of delayed graft function

Publications (1)

Publication Number Publication Date
BR0207434A true BR0207434A (pt) 2004-07-06

Family

ID=26245749

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0207434-6A BR0207434A (pt) 2001-02-22 2002-02-21 Uso de agentes de domiciliação acelerada de linfócitos para a fabricação de um medicamento para o tratamento de função retardada de enxertos

Country Status (11)

Country Link
US (2) US20040087662A1 (https=)
EP (1) EP1368015B1 (https=)
JP (1) JP4318921B2 (https=)
CN (1) CN100479814C (https=)
AT (1) ATE335475T1 (https=)
BR (1) BR0207434A (https=)
CA (1) CA2435739A1 (https=)
DE (1) DE60213766T2 (https=)
ES (1) ES2267993T3 (https=)
PT (1) PT1368015E (https=)
WO (1) WO2002067915A1 (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2322442T3 (es) * 2001-06-08 2009-06-22 Novartis Ag Tratamiento o profilaxis del rechazo de injertos de celulas productoras de insulina.
BR0306811A (pt) 2002-01-11 2004-10-26 Sankyo Co Composto, éster farmacologicamente aceitável do mesmo, composição farmacêutica e métodos para prevenção ou tratamento de doenças autoimunes, da artrite reumatóide e da rejeição causada pelo transplante de vários órgãos em um mamìfero
JP2005272453A (ja) 2004-02-24 2005-10-06 Sankyo Co Ltd アミノアルコール化合物
CN101014329B (zh) * 2004-07-16 2010-09-08 杏林制药株式会社 用于对器官或组织的移植的排异反应或骨髓移植的移植物抗宿主反应预防或治疗的药物组合物
EP1806338B1 (en) * 2004-10-12 2016-01-20 Kyorin Pharmaceutical Co., Ltd. Process for producing 2-amino-2-[2-[4-(3-benzyloxy-phenylthio)-2-chlorophenyl[ethyl]-1,3-propanediol hydrochloride and hydrates thereof. and intermediates the production thereof
SI1932522T1 (sl) * 2005-10-07 2012-08-31 Kyorin Seiyaku Kk Terapevtsko sredstvo za jetrno bolezen, ki vsebuje 2-amino-1,3- propandiolni derivat kot aktivno sestavino
TWI389683B (zh) * 2006-02-06 2013-03-21 Kyorin Seiyaku Kk A therapeutic agent for an inflammatory bowel disease or an inflammatory bowel disease treatment using a 2-amino-1,3-propanediol derivative as an active ingredient
MX2009001457A (es) * 2006-08-08 2009-02-19 Kyorin Seiyaku Kk Derivados de aminoalcohol e inmunosupresores que contienen lo mismo como ingrediente activo.
JP5188972B2 (ja) * 2006-08-08 2013-04-24 杏林製薬株式会社 アミノリン酸エステル誘導体及びそれらを有効成分とするｓ１ｐ受容体調節剤
WO2009099174A1 (ja) 2008-02-07 2009-08-13 Kyorin Pharmaceutical Co., Ltd. アミノアルコール誘導体を有効成分とする炎症性腸疾患の治療剤又は予防剤

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3928572A (en) * 1971-02-11 1975-12-23 Ayerst Mckenna & Harrison Myriocin and process of preparation
US5604229A (en) * 1992-10-21 1997-02-18 Yoshitomi Pharmaceutical Industries, Ltd. 2-amino-1,3-propanediol compound and immunosuppressant
ES2230571T3 (es) * 1995-12-28 2005-05-01 Mitsubishi Pharma Corporation `composicion farmaceutica destinada para la administracion topica que comprende el 2-amino-2-(2-(4-octilfenil)etil) propan-1,3-diol para el tratamiento de las enfermedades causadas por una alteracion inmunitaria.
GB9624038D0 (en) * 1996-11-19 1997-01-08 Sandoz Ltd Organic compounds
ATE298740T1 (de) * 1997-04-04 2005-07-15 Mitsubishi Pharma Corp 2-aminopropan-1,3-diol-verbindungen, ihre medizinische anwendung und zwischenprodukte zu ihrer synthese
JPH1180026A (ja) * 1997-09-02 1999-03-23 Yoshitomi Pharmaceut Ind Ltd 新規免疫抑制剤、その使用方法およびその同定方法
ES2322442T3 (es) * 2001-06-08 2009-06-22 Novartis Ag Tratamiento o profilaxis del rechazo de injertos de celulas productoras de insulina.

Also Published As

Publication number Publication date
US20040087662A1 (en) 2004-05-06
JP4318921B2 (ja) 2009-08-26
CA2435739A1 (en) 2002-09-06
JP2004527490A (ja) 2004-09-09
US20080015261A1 (en) 2008-01-17
ES2267993T3 (es) 2007-03-16
DE60213766T2 (de) 2007-08-02
HK1060855A1 (en) 2004-08-27
ATE335475T1 (de) 2006-09-15
CN100479814C (zh) 2009-04-22
EP1368015A1 (en) 2003-12-10
DE60213766D1 (de) 2006-09-21
PT1368015E (pt) 2006-12-29
WO2002067915A1 (en) 2002-09-06
EP1368015B1 (en) 2006-08-09
CN1492757A (zh) 2004-04-28

Similar Documents

Publication Publication Date Title
CY1119601T1 (el) Προαγωγεις αποπτωσης
BR0309492A (pt) Uso de pelo menos um álcool ramificado alcoxilado
BR0309581A (pt) Derivados de nucleosìdeo para tratamento de infecção por vìrus de hepatite c
BRPI0412404A (pt) uso de rapamicina e de derivado da rapamicina para o tratamento da perda óssea
ATE340844T1 (de) Stabile, wässerige zusammensetzungen zur behandlung von oberflächen , insbesondere geweben
CO5221115A1 (es) Nuevos compuestos fungicidas
UA88463C2 (ru) Фармацевтическая композиция, которая содержит соединение 1, и процесс лечения вич-инфекции
ATE281431T1 (de) Resorcin-derivate
CY1111050T1 (el) Φωσφονικα, μονοφωσφοναμιδικα, διφωσφοναμιδικα για την αγωγη των ιϊκων παθησεων
WO2004039248A3 (en) Repairing or replacing tissues or organs
WO2004031129A3 (en) Compounds for use in the treatment of autoimmune diseases, immuno-allergical diseases and organ or tissue transplantation rejection
AU1565300A (en) Anti-germinating method for tubers and bulbs using eugenol and/or isoeugenol
BR0207434A (pt) Uso de agentes de domiciliação acelerada de linfócitos para a fabricação de um medicamento para o tratamento de função retardada de enxertos
ES2194535T3 (es) 4-trifluorometil-3-oxazolilpiridinas, procedimiento para su preparacion, agentes que las contien y su uso como agente parala lucha contra organismos dañinos.
TR199901104T2 (xx) Farmas�tik bile�ikler.
MY122877A (en) Composition.
DK1178726T3 (da) Vandig opløsning til konservering af væv og organer
PA8582201A1 (es) Indoles 2,7-sustituidos
AR036581A1 (es) Composicion herbicida
ECSP066481A (es) Formulaciones que contienen cobre
WO2006034001A3 (en) Methods of treating hiv infection
WO2004091436A3 (en) Methods and compositions for treating ocular disease
EA200100141A1 (ru) Терапевтическая композиция на основе изофлавоноидов для применения в лечении опухолей цитотоксическими агентами
DE602004013011D1 (de) Haarbehandlungszusammensetzungen
BR0009194A (pt) Composição do resorcinol

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 9A ANUIDADE(S).

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2103 DE 26/04/2011.